Keywords
How to Cite
Abstract
Gold complexes (GC) reveal antitumor activity against xenografts of human tumors as well as against transplantable animal tumors in vivo and demonstrate cytotoxic effect against the wide spectrum of human tumor cells in vitro. GC had been effective against tumors with the acquired resistance to the platinum compounds. It is revealed the strong difference between mechanism of action of GC and platinum derivatives. Proteins, mainly thioredoxin reductase and proteasoma 26S, are the principal targets for the GC action but not for the platinum derivatives impact. Thioredoxin reductase and proteasoma 26S activity inhibition by GC leads to the development of the apoptosis mainly by the mitochondrial way in tumor cells.References
Корман Д.Б. Мишени и механизмы действия противоопухолевых препаратов, 2014. -Москва, «Практическая медицина». - С. 333.
Островская Л.А., Воронков М.Г., Корман Д.Б. и др. Полиакрилаты благородных металлов, как потенциальные противоопухолевые препараты // Биофизика. - 2014. - Т 59. - вып. 4. - С. 785-789.
Островская Л.А., Грехова А.К., Корман Д.Б. и др. Клеточные эффекты противоопухолевого препарата аурумакрил // Биофизика - 2017. - Т. 62. - вып. 3 - С. 598-603.
Островская Л.А., Корман Д.Б., Грехова А.К. и др. Экспериментальное исследование противоопухолевого эффекта препарата аурумакрил // Известия АН, серия химическая. - 2017. - № 12. - С. 2333-2338.
Платэ Н.А., Васильев А.Е. Физиологически активные полимеры, 1986. - Москва, «Химия». - С. 293.
Радченко Ш., Абзаева К.А., Корман Д.Б. и др. Супертушение флюоресценции интеркалированного в ДНК цианинового красителя при комплексообразовании с полиакрилатом золота // Химия высоких энергий. - 2017. - Т. 52. - № 3. - С. 256-257.
Aldinucci D., Lorenzon I.D., Stefan L. et al. Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamato derivatives on human acute myeloid leukemia cells in vitro // Anticancer Drugs. - 2007. - Vol. 8. - P. 323-332.
Altaf M., Monim-ul-Mehboob M., Kawde A.N. et al. New bipiridin gold(III) dithiocarbamato-containing complexes exerted a potent anticancer activity against cisplatin-re-sistant cancer cells independent of p53 status // Onco-target. - 2017. - Vol. 8. - P 490-505.
Cattaruza L., Fregona D., Mongiat M. et al. Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts // Int. J. Cancer. - 2011. - Vol. 128. - P. 206-215.
Celegato M., Fregona D., Mongiat M. et al. Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts // Future Med.Chemestry. - 2014. - Vol. 6. - P. 1249 -1263.
Celegato M., Borghese C., Casagrande N. et al. Pre-clinical activity of repurposed drug auranofin in classical Hodgkin lymphoma // Blood. - 2015. - Vol. 126. - P. 1394-1397.
Chen X., Shi X., Wang X., Liu J. Novel use of old drug: anti-reumatic agent auranofin overcomes imatinib-resis-tance of chronic myeloid leukemia cells // Cancer Cell Micrroenviron. - 2014. - № 1. - e415.
Chen X., Shi X.,Zhao C. et al. Anti-reumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl dependent and undependet mechanisms // Oncotarget. - 2014. - Vol. 19. - P. 9118-9132.
Chow H., Sun R.W., Lam J.B. et al. A gold(III) porphyrin complex with antitumor properties targets the Wut/ß-catenin pathway // Cancer Res. - 2010. - Vol. 70. - P.329-337.
Chung C.Y, Fung S.K., Tong K.C. et al. A multi-functional PEGylated gold(III) compound: potent anti-cancer properties and self-assembly into nanostructures for drug co-delivery // Chem.Soc. - 2011. - Vol. 8. - P. 1942 -1953.
De Ameida A.M., de Oleveira B.A., de Castro P.P. Lypophilic gold(III) complexes with 1,3,4-oxadiazol-2-thione or 1,3-thriazolidine-2- thione moieties: synthesis and their cytotoxic and antimicribial activities // Biometals. - 2017. - Vol. 30. - P. 841-857.
Fan C. Zheng W., Fu X. et al. Enhancement of aura-nofin-induced lung cancer cell apoptosis by selenocys-tine, a nature inhibitor of TrxRI in vitro and in vivo // Cell Death Dis. - 2014. - № 5. - e. 1191 ( 1038/cddis.2014.32). DOI: 10.1038/cddis.2014.32
Fiscus W., Saba N., Shen M. et al. Auranofin induces lethal oxidative and endoplaplasmic reticulum stress and exerts potent precinical activity against chronic lymphocytic leukemia // Cancer Res. - 2014. - Vol. 74. - P. 2520-2532.
Frezza M., Hindo S., Chen D. et al. Nobel metals and metal complexes as platforms for cancer therapy // Curr. Pharm. Des. - 2010. - Vol. 16. - P. 1813-1825.
Gandin V., Fernandes A.P., Rigobello M.P. Cancer cell death induced by phosphine gold(I) compounds targeting thoredoxin reductase // Biochem. Pharmacol. - 2010. - Vol. 78. - P. 90-101.
He M.F., Gao X.P., Li S.C. et al. Anti-angiogenic effect of auranofin on HEVECs in vitro and zebrafish in vivo // Eur. J. Pharmacol. - 2014. - Vol. 740. - P. 240-247.
Iwasama S., Yamano Y, Takiguchi Y. et al. Upregulation of thioredoxin reductase 1 in human oral squamous cell carcinoma // Oncol. Rep. - 2011. - Vol. 25. - P. 637644.
Kim I.S., Jin J.Y, lee H., Park S.I. Auranofin induces apoptosis and when combined with retinoic acid enhances dif-ferantion of acute promielocytic leukemia cells in vitro // Br. J. Pharmacol. - 2004. - Vol. 142. - P. 749-755.
Kim N.H., Lee M.Y, Park S.J. Auranofin blocks interleukin-6 signaling by inhibitibg phosphorylation of JAK and STAT3 // Immunology. - 2007. - Vol. 122. - P. 607614.
Kim N.H., Park H.J., Oh M.K., Kim I.S. Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activiry in MDA-MB-231 human breast cancer cells // BMB Rep. - 2013. - Vol. 13. - P. 59-64.
Kondom M.N., Ronconi L., Celegato M. et al. Toward selective delivery of chemotherapeutics into tumor cells by targeting peptide treansporters: tailorad gold-based anticancer peptidomimetics //J. Med. Chem. - 2012. - Vol. 55. - P. 2212-2226.
Kostova I. Gold coordination complexes anticancer agents // Anti-cancer Agents in Med. Chem. - 2006. - Vol. 6. - P. 19-32.
Landini I., Lapucci A., Pratesi A. et al. Selection and char-actertization of a human ovarian cancer cell line resistant to auranofin // Oncotarget. - 2017. - Vol. 8. - P. 96062-96078.
Li H., Hu J., Wu S. et al. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in nonsmall cell lung cancer cells // Oncotarget. - 2016. - Vol. 7. - P. 3548-3558.
Lincoln D.T., Al-Yatama F., Mohammed F.M. et al. Tio-redoxin and thioredoxin reductase expression in thyroid cancer depends on tumor agressivenes // Anticancer Rers. - 2010. -Vol. 30. - P. 767-775.
Liu J.J., Liu Q., Wei H.L. et al. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells // Pharmazie. - 2011. - Vol. 66. - P. 440-444.
Liu Y, Li Y, Yu S., Zhao G. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents // Curr. Drug Targets. - 2012. - Vol. 13. - P. 1432-1444.
Liu C., Liu Z., Li M. et al. Enhancement of auranofininduced apoptosis in MCF-7 human breast cell by selenocystine, a synergistic inhibitor of thioredoxin reductase // Plos. One - 2013. - Vol. 8(1). - e.53945 ( ). DOI: 10.1371/Jornal.pone.0053945
Liu N., Li X., Huang H. et al. Clinically used antireumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth // Oncotarget. - 2014. - Vol. 5. - P. 5433-5471.
Lu J., Holmgren A. The thioredoxin antioxidant system // Free Radical Biol. Med. - 2014. -Vol. 66. - P. 7587.
Lum C.T., Yang Z.F., Li H.Y Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma // Int. J. Cancer. - 2006. - Vol. 118. - P. 1527-1538.
Marcon G., Carotti S., Coornello M. et al. Gold(III) complexes with bypyridil ligands: solution chemestry, cytotoxi-cyty and DNA binding properties // J. Med. Chem. - 2002. - Vol. 45. -P. 1672-1677.
Markowska A., Kospzak B., Jaszczynska-Nowinka K. et al. Nobel metals in oncology // Comtemp. Oncol. (Pozn.). - 2015. - Vol. 19. - P. 271-275.
Marzano C., Gandin V., Fold A. et al. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cis-platin-resistant human ovarian cancer cells // Free Rad. Biol. Med. - 2007. -Vol. 42. - P. 872-881.
Marzano C., Ronconi L., Chiara F. et al. Gold(III)-dithio-carbamato anticancer agents: activity: toxicology and histopathological studies in rodents // Int. J. Cancer. - 2011. - Vol. 129. - P. 487-496.
Meier S.M., Gerner C., Keppler B.K. et al. Mass spectrometry uncovers molereactivities of coordination and organometallic gold(III) drug candidates in competitive experiments that correlate with their effects // Inorg. Chem. - 2016. - Vol. 255. - P. 424-4259.
Messori L., Orioli P., Tempi C., Marcon G. Interactions of selected gold(III) complexes with calf thymus DNA // Biochem. Biophys. Res. Comm. - 2001. - Vol. 281. - P. 352-360.
Micale N., Schirmeister T., Ettari R. et al. Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activites // J. Inorg. Biochem. - 2014. - Vol. 141. - P. 79-82.
Milacic V., Chen D., Ronconi L. et al. A novel anticancer gold(III) didthiocarbamato compound inhibits the activity of a purified 20S proteosoma and 26S proteosoma in human breast cancer cell culteres and xenografts // Cancer Res. - 2006. - Vol. 66. - P. 10478-10486.
Nakaya A., Sagawa M., Muto A. et al. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kB activity // Leuk. Res. - 2011. - Vol. 35. - P. 242-249.
Nardon C., Schmitt S.M., Yang H. et al. Gold(III)-di-thiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia // PloS One. - 2014. - Vol. 9(1). - e844248.
Nardon C., Boscutti G., Fregona D. Beyond platinums: gold complexes as anticancer agents // Anticancer Res. - 2014. - Vol. 34. - P. 487-492.
Nardon C., Chiara F., Brustolin L. et al. Gold(III)-pyrro-lidine dithiocarbamato derivaties as antineoplastic agents // Chemestry open. - 2015. - Vol. 4. - P. 183-191.
Nardon G., Pettenuzza N., Fregona D. Gold complexes for therapeutic purpose: an update patent review (20102015) // Curr. Med. Chem. - 2016. - Vol. 23. - P. 3374-3403.
Nobili S., Mini E., Landini I. et al. Gold compounds as anticancer agents:chemistry, cellular pharmacology and preclinical studies // Med. Res. Rev. - 2010. - Vol. 30. - P. 550-580.
Oomen D., Yiannakis D. BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranifin // Mut. Res. - 2015. - Vol. 784-785. - P. 8-15.
Ostrovskaya L.A., Voronkov M.G., Korman D.B. et al. Experimental Study of Antitumor Activity of Polymetalacry-lates against Animal Trasplantable Tumors // J. of Cancer Therapy. - 2010. - Vol. 1. - № 2. - P. 59-65.
Park S.G., Lee J.G., Berek J.S., Hu M.Y Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53 // Int. J. Oncol. - 2014. - Vol. 45. -P. 1691-1698.
Park N., Chun YJ. Auranofin promotes mitochondrial apoptosis by induction annexinA5 expression and translocation in human prostate cancer cell // J. Toxicol. Environ. Health. - 2014. - Vol. 27. - P. 1467-1476.
Pavic A., Glisic B.D., Vojnovic C. et al. Mononuclear gold(III) complexes with phenanthroline ligands as efficient inhibitors of angiogenesis: a comparative study with auranofin and sunutuniub // J. Inorg. Biochem. - 2017. - Vol. 174. - P. 156-168.
Pessetto Z.Y, Weir S.J., Sethi G. et al. Drug repurposing for gastrointestinal stromal tumor // Mol. Cancer Ther. - 2013. - Vol. 12. - P. 1299-1309.
Rackham O., Nichols S.J., Leedman P.J. et al. A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics target to mitochondria // Biochem. Pharmacol. - 2007. - Vol. 74. - P. 992-1002.
Radenkovic F., Holland O., Vanderlelie J.J., Petkins A.V Selective inhibition of endogenous antioxidants with auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation // Biochem. Pharmacol. - 2017. - DOI: 10.1016/j.bcp.2017.09.009
Rigobello M.P., Folda A., Dahi B. et al. Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T-cells // Europ. J. Pharm. - 2008. - Vol. 582. - P. 26-34.
Ronconi L., Mazano C., Zanello P. et al. Gold(III) dithiocarbamate derivatives for the treatment of cancer solution chemestry. DNA binding and hemolytic properties // J. Med. Che. - 2006. -Vol. 49. - P. 1648-1657.
Ronconi L., Aldinucci D., Don Q.P. Fregona D. Latest insights into anticancer activity of gold(III) -dithiocarbamato complexes // Anticancer Agents Med.Chem. - 2010. - Vol. 10. - P. 283-292.
Sachweh M.C., Stafford W.E., Drummond C.J.et al. Redox effects and cytotoxic profiles of MJ25 and auranofin toward malignant melanoma cells // Oncotarget. - 2015. - Vol. 6.р - P. 16488-16506.
Saggioro D., Rigobello M.P., Paloschi L. et al. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway // Chem.Biol. - 2007. - Vol. 14. - P. 1128-1139.
Sanchez-de-Diego C., Marmol I., Perez R. et al. The anticancer effect related to disturbances in redox balance on Caco-2 cells caused by an alkynyl gold(1) complex // J.Inorg. Biochem. - 2017. - Vol. 166. - P. 108-121.
Sun R.W., Li C.K., Ma D. et al. Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure // Chemistry. - 2010. - Vol.16. - P. 3097-3111.
To Y.F., Sun R.W., Chen Y. et al. Gold (III) porphirin complexes is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo // Intern. J. Cancer. - 2009. - Vol. 124. - P. 1971-1979.
Topkas E., Cai N., Cumming A. Auranofin is a potent suppressor of osteosarcoma metastasis // Oncotarget. - 2016. - Vol. 7. - P. 831-844.
Tu S., Sun R.W., Lin C.M. et al. Gold(III)pophyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon Cancer // Cancer. - 2009. - Vol. 114. - P. 4459-44695.
Wang Y, He Q.Y, Sun R.W et al. Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug // Eur. J. Pharmacol. - 2007. - Vol. 554. - P. 115-122.
Wang y., Bonzakoura S., de Mey S.et al. Auraofin ra-diosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species // Oncotarget. - 2017. - Vol. 8. - P. 35728 -35742.
You B.R., Park W.H. Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion // Oncol. Rep. - 2016. - Vol. 35. - P. 546-551.
Zhang X., Frezza M., Milacic V. et al. Inhibition of tumor proteasome activity by dithocarbamato comlexes via both redox-dependent and undependent process // J. Cell Biochem. - 2010. - Vol. 109. - P. 162-172.
Zhang J., Li X., Han X. et al. Targeting the thioredoxin system for cancer therapy // Trends Pharmacol. Soc. - 2017. - Vol. 38. - P. 794-808.
Zhang B., Zhang J., Peng S.et al. Thioredoxin reductase inhibitors: a patent view // Expert Opin. Ther. Pat. - 2017. - Vol. 27. - P. 547-556.
Zou T., Lum C.T, Lok C.N. et al. Chemical biology of anticancer gold(III) and gold(I) complexes // Chem. Soc. Rev. - 2015. - Vol. 44. - P. 8786-8801.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018